Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease

Next Previous
Search
Trial Profile

A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latiglutenase (Primary)
  • Indications Coeliac disease
  • Focus Therapeutic Use
  • Acronyms CeliacShield; gluten-challenge study
  • Sponsors ImmunogenX

    • Most Recent Events

    • 20 May 2024 According to an Entero Therapeutics media release, the company presented data from this trial as poster at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.
    • 16 May 2024 According to a Entero Therapeutics media release, company First Wave BioPharma Changes Name to Entero Therapeutics.
    • 24 Apr 2024 According to a First Wave Biopharma media release, company announced research generated from two previously completed Phase 2 clinical trials (NCT03585478 and NCT04243551) of latiglutenase has been published in the special issue "Recent Advances in Gluten-Free Diet and Celiac Disease" in the peer-reviewed scientific journal, Nutrients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top